ONIVYDE®
is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die.
PharmaEngine, Inc.
We Race With You
Virtual Pharmaceutical Company Business Model
Latest News
-
2026-07-27
PharmaEngine announces South Korea's MFDS approval of PEP08 Phase I clinical trial for solid tumor cancers
-
2025-11-17
ONIVYDE® with oxaliplatin, fluorouracil and leucovorin will be included in Taiwan NHI for first-line treatment of metastatic pancreatic adenocarcinoma
-
2025-10-20
PharmaEngine announces first patient dosed in PEP08 Phase I clinical trial for solid tumor cancers